ezetimibe has been researched along with empagliflozin in 2 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (empagliflozin) | Trials (empagliflozin) | Recent Studies (post-2010) (empagliflozin) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 1,429 | 313 | 1,395 |
| Protein | Taxonomy | ezetimibe (IC50) | empagliflozin (IC50) |
|---|---|---|---|
| Sodium/glucose cotransporter 2 | Homo sapiens (human) | 0.0031 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Chung, KS; Gee, HY; Kim, DY; Park, JY | 1 |
2 other study(ies) available for ezetimibe and empagliflozin
| Article | Year |
|---|---|
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models.
Topics: Adult; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Glucose; Humans; Liver; Mice; Non-alcoholic Fatty Liver Disease | 2023 |